Sionna Therapeutics, Inc. (NASDAQ:SION) Receives Average Recommendation of “Hold” from Brokerages

Sionna Therapeutics, Inc. (NASDAQ:SION) has earned an average rating of “Hold” from the thirteen research firms that are covering the stock, MarketBeat reports. One equities research analyst has rated the stock with a sell recommendation, eleven have assigned a hold recommendation and one has assigned a buy recommendation to the company. The average 1 year price objective among analysts that have updated their coverage on the stock in the last year is $42.2222.

SION has been the topic of several research analyst reports. JonesTrading downgraded Sionna Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Monday, August 10th. Stifel Nicolaus reiterated a “hold” rating and issued a $7.00 price target on shares of Sionna Therapeutics in a research note on Monday, August 10th. Weiss Ratings reissued a “sell (d-)” rating on shares of Sionna Therapeutics in a report on Wednesday, August 5th. Raymond James Financial lowered Sionna Therapeutics from a “strong-buy” rating to a “market perform” rating in a research note on Monday, August 10th. Finally, Wall Street Zen downgraded shares of Sionna Therapeutics from a “sell” rating to a “strong sell” rating in a report on Saturday.

Insider Activity at Sionna Therapeutics

In other Sionna Therapeutics news, Director Orbimed Advisors Llc sold 85,918 shares of the company’s stock in a transaction that occurred on Tuesday, July 7th. The shares were sold at an average price of $44.86, for a total transaction of $3,854,281.48. Following the transaction, the director owned 2,469,959 shares in the company, valued at approximately $110,802,360.74. This represents a 3.36% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Peter A. Thompson sold 85,918 shares of the company’s stock in a transaction that occurred on Tuesday, July 7th. The shares were sold at an average price of $44.86, for a total transaction of $3,854,281.48. Following the transaction, the director owned 2,469,959 shares in the company, valued at $110,802,360.74. The trade was a 3.36% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders have sold 403,726 shares of company stock worth $18,259,354. 5.10% of the stock is owned by insiders.

Hedge Funds Weigh In On Sionna Therapeutics

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. BlackRock Inc. acquired a new position in shares of Sionna Therapeutics in the second quarter valued at about $64,875,000. Eventide Asset Management LLC purchased a new position in shares of Sionna Therapeutics in the fourth quarter worth about $26,290,000. Vanguard Group Inc. lifted its holdings in shares of Sionna Therapeutics by 81.4% during the third quarter. Vanguard Group Inc. now owns 1,143,154 shares of the company’s stock worth $33,620,000 after purchasing an additional 512,803 shares during the period. State Street Corp boosted its position in Sionna Therapeutics by 188.7% in the fourth quarter. State Street Corp now owns 693,395 shares of the company’s stock valued at $28,526,000 after buying an additional 453,196 shares during the last quarter. Finally, Jennison Associates LLC boosted its position in Sionna Therapeutics by 30.1% in the first quarter. Jennison Associates LLC now owns 1,451,220 shares of the company’s stock valued at $58,179,000 after buying an additional 335,942 shares during the last quarter.

Sionna Therapeutics Stock Up 0.5%

Shares of SION opened at $5.94 on Wednesday. The company has a 50 day moving average of $38.07 and a two-hundred day moving average of $38.64. Sionna Therapeutics has a twelve month low of $4.01 and a twelve month high of $54.97. The company has a market cap of $268.55 million, a price-to-earnings ratio of -2.72 and a beta of 1.32.

Sionna Therapeutics (NASDAQ:SION) last issued its quarterly earnings results on Thursday, August 6th. The company reported ($0.66) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.64) by ($0.02). On average, sell-side analysts expect that Sionna Therapeutics will post -2.55 EPS for the current year.

Sionna Therapeutics Company Profile

Sionna Therapeutics is a clinical-stage biotechnology company dedicated to developing next-generation RNA therapeutics for oncology and immunology indications. Leveraging proprietary lipid nanoparticle and coacervate delivery technologies, the company aims to overcome key challenges associated with stability, targeting and immune activation that have historically limited the clinical performance of mRNA-based medicines. Its strategic focus spans both solid tumors and hematological malignancies, as well as selected autoimmune disorders, reflecting a broad ambition to harness the power of messenger RNA in diverse therapeutic areas.

At the heart of Sionna’s approach is a platform that combines optimized ionizable lipids with bespoke surface chemistries to enhance payload delivery, intracellular release and endosomal escape.